Immix Biopharma, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Immix Biopharma, Inc. now
Current reporting with the operating signal separated from the noise.
Immix Biopharma, Inc. Receives FDA RMAT Designation for CAR-T Therapy NXC-201 in Relapsed/Refractory AL Amyloidosis
The story matters when it changes Immix Biopharma, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Immix Biopharma, Inc.'s (NASDAQ:IMMX) recent US$2.9m market cap decline means a loss of US$194k for insiders who bought this year
The story matters when it changes Immix Biopharma, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest IMMX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Immix Biopharma, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →